Favorable Outcomes with New Generation Transcatheter Heart Valves in Bicuspids

Original Title: Bicuspid Aortic Valve Stenosis Favorable Early Outcomes UIT a Next-Generation Transcatheter Heart Valve in a Multicenter Study. Reference: Gidon Y. Perlman J Am Coll Cardiol Interv 2016;9:817-24

Courtesy of Dr. Carlos Fava.

Congenital bicuspid aortic valves are infrequent and are associated with severe calcification in elderly patients.

Transcatheter aortic valve replacement to treat bicuspid aortic stenosis is challenging because of their anatomical characteristics and there is not enough evidence on its outcomes.

This study included 51 patients with bicuspid aortic valves receiving an Edwards SAPIENS 3.

Mean patient age was 76 and little more than half were women with STS score 5.2±3.7%.

The procedure was done in 20 patients under sedation and local anesthetics, two via carotid access and the rest via femoral.

There were no deaths, malposition, embolization, second valves or conversion to surgery.

At 30 days, the gradient decreased from 49.4±16 mmHg at baseline to 11.2±4.7 mmHg, and the area increased from 0.7±0.2 cm2 to 1.7±0.3 cm2. There was none/trivial aortic regurgitation in 32 patients and none presented moderate or severe regurgitation.

During the first month, there were 2 deaths, 2 major vascular complications and 12 patients required a definite pacemaker.

The need for a definite pacemaker was associated with implantation >8 mm below annulus level (low implantation, 55% need for pacemaker vs. 10% higher implantation; p=0.01).

Conclusion
TAVI in bicuspid valves with new generation devices was feasible and effective with a favorable performance and no cases of moderate or severe aortic regurgitation.

Editorial Comment
Bicuspid valves are different in morphology, are more calcified and are associated with moderate and severe aortic regurgitation.

New generation valves improve performance and encourage us to advance with this group, improving accuracy of position implantation position in order to avoid pacemaker implantation after TAVI.
Courtesy of Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

TEER plus optimal medical therapy versus medical therapy alone in functional mitral regurgitation

Mitral regurgitation (MR) is a highly prevalent valvular heart disease that, in advanced stages and when left untreated, is associated with reduced quality of...

VECTOR: First Percutaneous Aorto-Coronary Bypass Case, a New Conceptual Approach

Coronary obstruction represents one of the most severe complications associated with transcatheter aortic valve implantation, particularly in valve-in-valve scenarios involving surgical bioprostheses, narrow aortic...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

TEER plus optimal medical therapy versus medical therapy alone in functional mitral regurgitation

Mitral regurgitation (MR) is a highly prevalent valvular heart disease that, in advanced stages and when left untreated, is associated with reduced quality of...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...